The partnership will initially focus on low-abundance biomarkers supporting translational research in Alzheimer's disease.

Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...